More interestingly, recent evidence has highlighted that AIM2 could improve the anti-tumor effects of radiotherapy by triggering IL-1 signaling in DCs, leading to their activation and enhancement of T cell immunity [118]. This evidence concerns the gene IL1B and neoplasm.